Literature DB >> 23670230

Association of biomarkers of lipid modification with functional and morphological indices of coronary stenosis severity in stable coronary artery disease.

Olivier Muller1, Argyrios Ntalianis, William Wijns, Leen Delrue, Karen Dierickx, Reto Auer, Nicolas Rodondi, Fabio Mangiacapra, Catalina Trana, Michalis Hamilos, Emmanuel Valentin, Bernard De Bruyne, Emanuele Barbato, Jozef Bartunek.   

Abstract

Biomarkers of blood lipid modification and oxidative stress have been associated with increased cardiovascular morbidity. We sought to determine whether these biomarkers were related to functional indices of stenosis severity among patients with stable coronary artery disease. We studied 197 consecutive patients with stable coronary artery disease due to single vessel disease. Fractional flow reserve (FFR) ≤ 0.80 was assessed as index of a functionally significant lesion. Serum levels of secretory phospholipase A2 (sPLA2) activity, secretory phospholipase A2 type IIA (sPLA2-IIA), myeloperoxydase (MPO), lipoprotein-associated phospholipase A2 (Lp-PLA2), and oxidized low-density lipoprotein (OxLDL) were assessed using commercially available assays. Patients with FFR > 0.8 had higher sPLA2 activity, sPLA2 IIA, and OxLDL levels than patients with FFR ≤ 0.8 (21.25 [16.03-27.28] vs 25.85 [20.58-34.63] U/mL, p < 0.001, 2.0 [1.5-3.4] vs 2.6 [2.0-3.4] ng/mL, p < 0.01; and 53.0 [36.0-71.0] vs 64.5 [50-89.25], p < 0.001 respectively). Patients with FFR > 0.80 had similar Lp-PLA2 and MPO levels versus those with FFR ≤ 0.8. sPLA2 activity, sPLA2 IIA significantly increased area under the curve over baseline characteristics to predict FFR ≤ 0.8 (0.67 to 0.77 (95 % confidence interval [CI]: 0.69-0.85) p < 0.01 and 0.67 to 0.77 (95 % CI: 0.69-0.84) p < 0.01, respectively). Serum sPLA2 activity as well as sPLA2-IIA level is related to functional characteristics of coronary stenoses in patients with stable coronary artery disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23670230     DOI: 10.1007/s12265-013-9468-x

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  31 in total

Review 1.  Routine invasive versus conservative management strategies in acute coronary syndrome: time for a "hybrid" approach.

Authors:  Pravin Pratap; Sameer Gupta; Michael Berlowitz; Michael Berlowtiz
Journal:  J Cardiovasc Transl Res       Date:  2011-12-13       Impact factor: 4.132

2.  Are high doses of intracoronary adenosine an alternative to standard intravenous adenosine for the assessment of fractional flow reserve?

Authors:  Gianni Casella; Marcus Leibig; Thomas M Schiele; Reiner Schrepf; Victoria Seelig; Hans-Ulrich Stempfle; Petra Erdin; Johannes Rieber; Andreas König; Uwe Siebert; Volker Klauss
Journal:  Am Heart J       Date:  2004-10       Impact factor: 4.749

3.  Fractional flow reserve in patients with prior myocardial infarction.

Authors:  B De Bruyne; N H Pijls; J Bartunek; K Kulecki; J W Bech; H De Winter; P Van Crombrugge; G R Heyndrickx; W Wijns
Journal:  Circulation       Date:  2001-07-10       Impact factor: 29.690

4.  Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease.

Authors:  Wolfgang Koenig; Carla Y Vossen; Ziad Mallat; Hermann Brenner; Joëlle Benessiano; Dietrich Rothenbacher
Journal:  Eur Heart J       Date:  2009-08-07       Impact factor: 29.983

5.  Fractional flow reserve and myocardial perfusion imaging in patients with angiographic multivessel coronary artery disease.

Authors:  Narbeh Melikian; Pieter De Bondt; Pim Tonino; Olivier De Winter; Eric Wyffels; Jozef Bartunek; Guy R Heyndrickx; William F Fearon; Nico H J Pijls; William Wijns; Bernard De Bruyne
Journal:  JACC Cardiovasc Interv       Date:  2010-03       Impact factor: 11.195

Review 6.  Intravascular imaging tools in the cardiac catheterization laboratory: comprehensive assessment of anatomy and physiology.

Authors:  Parham Eshtehardi; Jennifer Luke; Michael C McDaniel; Habib Samady
Journal:  J Cardiovasc Transl Res       Date:  2011-04-01       Impact factor: 4.132

Review 7.  Techniques for phenotyping coronary artery disease in the cardiac catheterization laboratory for applications in translational research.

Authors:  Michael Ragosta
Journal:  J Cardiovasc Transl Res       Date:  2011-03-29       Impact factor: 4.132

Review 8.  NADPH oxidase and cardiac failure.

Authors:  Junya Kuroda; Junichi Sadoshima
Journal:  J Cardiovasc Transl Res       Date:  2010-03-31       Impact factor: 4.132

Review 9.  Inflammation in atherosclerosis: from pathophysiology to practice.

Authors:  Peter Libby; Paul M Ridker; Göran K Hansson
Journal:  J Am Coll Cardiol       Date:  2009-12-01       Impact factor: 24.094

10.  Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy.

Authors:  Leslee J Shaw; Daniel S Berman; David J Maron; G B John Mancini; Sean W Hayes; Pamela M Hartigan; William S Weintraub; Robert A O'Rourke; Marcin Dada; John A Spertus; Bernard R Chaitman; John Friedman; Piotr Slomka; Gary V Heller; Guido Germano; Gilbert Gosselin; Peter Berger; William J Kostuk; Ronald G Schwartz; Merill Knudtson; Emir Veledar; Eric R Bates; Benjamin McCallister; Koon K Teo; William E Boden
Journal:  Circulation       Date:  2008-02-11       Impact factor: 29.690

View more
  3 in total

1.  Biomarkers and heart disease: what is translational success?

Authors:  Francis G Spinale; Craig M Stolen
Journal:  J Cardiovasc Transl Res       Date:  2013-06-04       Impact factor: 4.132

2.  The influence of exendin-4 intervention on -obese diabetic mouse blood and the pancreatic tissue immune microenvironment.

Authors:  Jinshui He; Chaowei Lian; Yanling Fang; Jinzhi Wu; Huowang Zhou; Xiaoling Ye
Journal:  Exp Ther Med       Date:  2016-09-12       Impact factor: 2.447

3.  Phospholipase A2 group IIA correlates with circulating high-density lipoprotein cholesterol and modulates cholesterol efflux possibly through regulation of PPAR-γ/LXR-α/ABCA1 in macrophages.

Authors:  Ling Liang; Qiang Xie; Changqing Sun; Yuanhui Wu; Wei Zhang; Weihua Li
Journal:  J Transl Med       Date:  2021-11-27       Impact factor: 5.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.